Accelr8 Posts Flat Revenues, Narrowed Loss in Fiscal Q1; Sheds No Light on BACcelr8r Availability

Dec 20, 2006

NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.

Total receipts for the three months ended Oct. 31 were flat at $86,000.

Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.

The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

This Week in Science

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Main menu